OpenLegislation

Paragraph 1

Changes not yet applied. Later legislation changes this provision in ways not yet written into the text below:

Subject to paragraphs 2 to 4 below, the applicant shall not be required, under paragraph 8 of Schedule 1, to provide particulars of the results of pharmacological and toxicological tests or of the results of clinical trials if he can demonstrate:

(a)

that the product is essentially similar to a product to which an existing product licence (not being one which relates solely to importation) applies and that the person responsible for placing that product on the market in the United Kingdom has consented to the pharmacological, toxicological or clinical references contained in the file on the original medicinal product being used for the purpose of examining the product in question;

(b)

by detailed references to published scientific literature presented in accordance with the second paragraph of Article 1 of Directive 75/318/EECf1 that the constituent or constituents of the medicinal product have a well established medical use, with recognised efficacy and an acceptable level of safety; or

(c)

that the product is essentially similar to a product which has been authorized within the European Economic Community in accordance with Community provisions in force, for not less than ten years and is marketed in the United Kingdom.

Annotations

Footnotes

f1

OJ No.L147, 9.6.75, p.1. The Directive was amended by Directive 89/341/EEC (OJ No.L142, 25.5.89, p.11), and the Annex to it was substituted by Directive 91/507/EEC (OJ No.L270, 26.9.91, p.32).